Publication

PPAR agonists in the treatment of atherosclerosis

Related publications (57)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

PPAR agonists in the treatment of atherosclerosis

Graph Chatbot

Chat with Graph Search

The Sirt1 activator SRT3025 provides atheroprotection in Apoe(-/-) mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression

Inflammatory and metabolic responses to high-fat meals with and without dairy products in men

Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice

Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice

Insights into the antiatherogenic molecular mechanisms of andrographolide against Porphyromonas gingivalis-induced atherosclerosis in rabbits

SUMOylation-Dependent LRH-1/PROX1 Interaction Promotes Atherosclerosis by Decreasing Hepatic Reverse Cholesterol Transport

Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice

Experimental peripheral arterial disease: new insights into muscle glucose uptake, macrophage, and T-cell polarization during early and late stages

Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice

Deletion of Sirt3 does not affect atherosclerosis but accelerates weight gain and impairs rapid metabolic adaptation in LDL receptor knockout mice: implications for cardiovascular risk factor development